SCHEMBL1962369

SCHEMBL1962369

CC(C)/C=C(/c1cccc(N(C)C)c1)c1cc2cccnc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
RECQL P46063 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
PTGDR2 Q9Y5Y4 3/20 0.37
CYP2C19 P33261 1/20 0.36
HTR6 P50406 3/20 0.34
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34
SIRT1 Q96EB6 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1962372 1.00 LMNA (0.38) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1959000 0.89 ALDH1A1 (0.40) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1959001 0.89 ALDH1A1 (0.40) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1963720 0.87 PTGDR2 (0.44) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1959403 0.87 ALDH1A1 (0.39) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1963722 0.87 PTGDR2 (0.44) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1962280 0.87 ALDH1A1 (0.41) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1962278 0.87 ALDH1A1 (0.41) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1959402 0.87 ALDH1A1 (0.39) LMNARECQLALDH1A1MAPTPTGDR2
SCHEMBL1962059 0.85 HDAC3 (0.43) LMNARECQLALDH1A1MAPTPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 LMNA 4695/4885RECQL 3296/4885ALDH1A1 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.